{"id":407342,"date":"2021-01-04T07:33:32","date_gmt":"2021-01-04T12:33:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=407342"},"modified":"2021-01-04T07:33:32","modified_gmt":"2021-01-04T12:33:32","slug":"allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AlloVir to Present at the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference <\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.\n<\/p>\n<p>\nAn audio-only webcast of the presentation will be available on January 11<sup>th<\/sup> on the Investors &amp; Press section of the AlloVir website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.allovir.com%2F&amp;esheet=52353245&amp;newsitemid=20210104005013&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.allovir.com&amp;index=1&amp;md5=2216cc3ca1cddb86be2c3d099c1e203c\">https:\/\/ir.allovir.com<\/a>. An archived replay of the presentation will be available for approximately 30 days following the presentation.\n<\/p>\n<p style=\"font-weight:normal\"><b>About AlloVir<\/b><\/p>\n<p>\nAlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company\u2019s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir\u2019s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.allovir.com&amp;esheet=52353245&amp;newsitemid=20210104005013&amp;lan=en-US&amp;anchor=www.allovir.com&amp;index=2&amp;md5=a8a5fdecb157b11598bfb192844f2a06\">www.allovir.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210104005013\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210104005013\/en\/<\/a><\/span><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Courtney Heath<br \/>\n<br \/>ScientPR<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AlloVirPR@scientpr.com\">AlloVirPR@scientpr.com<br \/>\n<\/a><br \/>617-872-2462\n<\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Medha Chadha<br \/>\n<br \/>AlloVir<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@allovir.com\">ir@allovir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210104005013\/en\/841466\/3\/AlloVir_Logo_FullColor%5B2%5D%5B2%5D%5B9%5D.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET. An audio-only webcast of the presentation will be available on January 11th on the Investors &amp; Press section of the AlloVir website at https:\/\/ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company\u2019s innovative and proprietary technology platforms &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-407342","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET. An audio-only webcast of the presentation will be available on January 11th on the Investors &amp; Press section of the AlloVir website at https:\/\/ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company\u2019s innovative and proprietary technology platforms &hellip; Continue reading &quot;AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T12:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-04T12:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-04T12:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET. An audio-only webcast of the presentation will be available on January 11th on the Investors &amp; Press section of the AlloVir website at https:\/\/ir.allovir.com. An archived replay of the presentation will be available for approximately 30 days following the presentation. About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company\u2019s innovative and proprietary technology platforms &hellip; Continue reading \"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-04T12:33:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-04T12:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-04T12:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210104005013r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allovir-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=407342"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/407342\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=407342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=407342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=407342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}